Atlas Trials

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Clinical trial NCT04235621 · TERMINATED

Trial details

NCT number
NCT04235621
Sponsor
Goldfinch Bio, Inc.
Status
TERMINATED
Study type
OBSERVATIONAL
Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseDiabetic Nephropathies
Start date
2019-12-20
Primary completion
2020-05-27
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.